openPR Logo
Press release

Anti-obesity Drugs Market CAGR To Exceed 21% by 2035, Due to The Growing Need for Anti-obesity Drugs | Roots Analysis

03-04-2025 02:32 PM CET | Health & Medicine

Press release from: Roots Analysis

Anti-obesity Drugs Market CAGR To Exceed 21% by 2035, Due to

According to our latest market report "Anti-obesity Drugs Market, till 2035 by Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players: Industry Trends and Global Forecasts", the global anti-obesity drugs market size is projected to reach USD 104.9 billion by 2035 from USD 12.8 billion in 2024, growing at a CAGR of 21.1% in the forecast period.

To Request for free sample please visit : https://www.rootsanalysis.com/reports/anti-obesity-drugs-market/request-sample.html

Anti-obesity drugs include a range of pharmaceutical treatments designed to assist individuals in managing obesity and associated concerns of chronic disorders, such as diabetes mellitus and cardiovascular disorders. These medications enhance weight loss by influencing appetite regulation, fat absorption and metabolism. It is worth mentioning that in the recent years, several new anti-obesity drugs have received regulatory approval, expanding the options available to patients, offering alternatives to bariatric surgery. Additionally, the ongoing advancements in drug formulation and delivery systems, coupled with the development of novel compounds, have led to the emergence of more effective and safer anti-obesity medications. Notably, the rise in telehealth services and digital therapeutics is further facilitating better patient engagement and adherence to the treatment regimens. Consequently, the aforementioned factors are likely to present lucrative market growth opportunities for drug developers and this domain is anticipated to experience enormous growth in the coming years.

Anti-obesity Drugs Market Segments

Based on the type of molecule, the market is segmented into biologics and small molecules

1. The small molecules segment is likely to capture the largest revenue share of around 55% in the anti-obesity drugs market in 2024.
2. The biologics segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 23.8%, during the forecast period.

Based on the active compound used, the market is segmented into tirzepatide, semaglutide, retatrutide, survodutide, cagrilintide and semaglutide, orforglipron, liraglutide, other active compounds

1. The semaglutide segment is likely to capture the largest revenue share of around 55% in the anti-obesity drugs market in 2024.
2. The tirzepatide segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 21.1%, during the forecast period.

Based on the mechanism of action, the market is segmented into GLP-1 agonists / GIP agonists, GLP-1 agonists / GCGR agonists, GLP-1 agonists, GLP-1 agonists / Amylin analogues, GLP-1 / GCGR / GIP agonists and other mechanisms of action

1. The GLP-1 agonists segment is likely to capture the largest revenue share of 65% in the anti-obesity drugs market in 2024.
2. The GLP-1 agonists / GIP agonists segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 21.1%, during the forecast period.

Based on the type of agonist, the market is segmented into single-agonists, dual-agonists and tri-agonists

1. The single-agonists segment is likely to capture the largest revenue share of around 70% in the anti-obesity drugs market in 2024.
2. The dual-agonists segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 25.7%, during the forecast period.

To request quote of this report, please visit
https://www.rootsanalysis.com/reports/anti-obesity-drugs-market/request-quote.html

Based on the action pathway, the market is segmented into centrally acting, peripherally acting, centrally acting and peripherally acting drugs

1. The centrally acting drugs segment is likely to capture the largest revenue share of around 85% in the anti-obesity drugs market in 2024.
2. The centrally acting drugs segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 22.6%, during the forecast period.

Based on the route of administration, the market is segmented into oral and parenteral route of administration

1. The segment for parenteral route of administration is likely to capture the largest revenue share of more than 95% in the anti-obesity drugs market in 2024.
2. The segment for oral route of administration is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 40.6%, during the forecast period.

Based on the regional insights, the market is segmented into North America, Europe, Asia-Pacific and Latin America

1. North America is likely to dominate the anti-obesity drugs market, by capturing the largest revenue share of nearly 70%, in 2024.
2. In Asia-Pacific, the anti-obesity drugs market is likely to demonstrate considerable growth with a relatively higher CAGR (~40%) during the forecast period.

Anti-obesity Drugs Market Regional Outlook

Based on the geographical regions, the anti-obesity drugs market can be segmented into four major regions, including North America, Europe, Asia-Pacific and Latin America. North America is anticipated to capture the majority share of the anti-obesity drugs market in 2024. The advanced healthcare infrastructure and research capabilities in North America enable drug developers to conduct extensive clinical trials, which is necessary to meet the required regulatory guidelines provided by the approval bodies. Further, the anti-obesity drugs domain in Asia-Pacific is accounted to be the fastest-growing segment of the market.

Key Report Takeaways

1. Presently, around125 players are engaged in the development of anti-obesity drugs; of these, around 55% players are headquartered in North America
2. A sizeable proportion (70%) of big pharma players have entered into various partnerships in order to expand their anti-obesity drug portfolios; followed by players (~20%) undertaking expansion initiatives
3. The anti-obesity drugs market is anticipated to grow at an annualized rate (CAGR) of 21.1%, till 2035; North America is expected to capture the majority share (~60%) of the market by 2035

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/anti-obesity-drugs-market.html

Anti-obesity Drugs Market Key Players
Examples of key companies engaged in anti-obesity drugs market (which have also been profiled in this market report) include (in alphabetic order) Adocia, AstraZeneca, Boehringer Ingelheim, CinFina Pharma, Eli Lilly, Gmax Biopharma, Hanmi Pharm, Jiangsu Hengrui Pharmaceuticals, Kallyope, Novo Nordisk, PegBio. Pfizer, QL Biopharm, Regeneron, Roche, Sciwind Biosciences, Viking Therapeutics and Zealand Pharma

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anti-obesity Drugs Market CAGR To Exceed 21% by 2035, Due to The Growing Need for Anti-obesity Drugs | Roots Analysis here

News-ID: 3896946 • Views:

More Releases from Roots Analysis

Gene switches have garnered significant attention from drug developers owing to their ability to control the activity of genetically modified cell products in vivo
Gene switches have garnered significant attention from drug developers owing to …
The global gene switch market size is estimated to grow from USD 795 million in 2025 to USD 2,478 million by 2035, representing a CAGR of 12.03% during the forecast period till 2035. Driven by numerous developmental breakthroughs and encouraging study results demonstrating the vast potential of adoptive cell therapies (ACT), including CAR-T cell therapies, TCR therapies, TILs and natural killer cell therapies, in the treatment of various complex disorders, this
Antibody Discovery Market Set to Soar to $6.6 Billion by 2035
Antibody Discovery Market Set to Soar to $6.6 Billion by 2035
Antibodies, also known as immunoglobulins, are Y-shaped glycoproteins that are produced by the immune system in response to foreign molecules (antigens) that enter the body. The term antigen refers to any substance that is capable of inducing an immune response, encompassing a diverse range of entities, including viruses, fungi, bacteria, proteins on the surface of cells, and non-living substances, such as toxins, chemicals and foreign particles. The global antibody discovery
Biopsy is defined as a procedure of removing or extracting tissue from the body through various methods, such as surgical, needle, laparoscopic techniques.
Biopsy is defined as a procedure of removing or extracting tissue from the body …
The global virtual biopsy market, valued at USD 0.73 billion in 2024, is projected to reach USD 0.78 billion in 2025 and USD 3.02 billion by 2035, representing a CAGR of 14.47% during the forecast period. This procedure plays a crucial role in the diagnosis or monitoring of certain medical conditions such as inflammatory disorders, immune disorders, oncological conditions, and several infections. By analyzing the cellular composition of the extracted tissue,
Big data in healthcare: transforms patient care, enhances efficiency, and unlocks new possibilities for personalized medicine
Big data in healthcare: transforms patient care, enhances efficiency, and unlock …
The global big data in healthcare market size is estimated to grow from USD 78 billion in 2024 to USD 540 billion by 2035, representing a CAGR of 19.20% during the forecast period till 2035. Big data in healthcare is the collection of large amounts of unstructured data from various sources, such as medical research, biometric data, electronic medical records, Internet of Medical Things (IoMT), social media, payer records, omics

All 5 Releases


More Releases for CAGR

[CAGR of 6.7%] Nanocoatings Market Size, Industry Share, CAGR, Regional Forecast …
The global Nanocoatings Market generated $10.7 billion in 2020, and is projected to reach $20.1 billion by 2030, growing at a CAGR of 6.7% from 2021 to 2030. The report provides an in-depth analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive scenario, and wavering market trends. Download sample PDF @ https://www.alliedmarketresearch.com/request-sample/2064 According to the report published by Allied Market Research,
[CAGR of 5.3%] Pigments Market Size, Industry Share, CAGR, Regional Forecast, 20 …
A recent report by Allied Market Research provides a detailed analysis of the pigments market, highlighting its robust growth. The industry was valued at $27.2 billion in 2022 and is projected to surge to $45.4 billion by 2032, exhibiting an impressive CAGR of 5.3% from 2023 to 2032. This research report identifies the growth drivers behind the market's expansion and delves into the market dynamics using advanced analytical frameworks
Enzymes Market Expansion CAGR of 4.9% CAGR Anticipated 2025-2034
The Enzymes Market report is an in-depth examination of the global Enzymes Market's general consumption structure, development trends, sales techniques, and top nations' sales. The research looks at well-known providers in the global Enzymes Market industry, as well as market segmentation, competition, and the macroeconomic climate. A complete Enzymes Market analysis takes into account a number of aspects, including a country's population and business cycles, as well as market-specific microeconomic
Waterproofing Membranes Market is Projected Grow at CAGR of 8% CAGR by 2033
The waterproofing membranes market is anticipated to witness a Compound Annual Growth Rate (CAGR) of 8.0% over the forecast period. By 2023, the estimated market value for waterproofing membranes is substantial, reaching US$ 31.5 billion. These waterproofing materials comprise thin, impermeable membranes designed to collaborate with asphalt, providing a protective shield for the structural integrity of buildings. The asphalt component in these membranes acts as a safeguard, preserving the underlying membrane
Electric Bed Market CAGR, Size, Share Grow USD 2,063 Million by 2030 CAGR 13.70%
Global electric bed market size is expected to be worth roughly USD 2,063 million by 2030, growing at a CAGR of more than 13.7% during the projected timeframe of 2022-2030, according to Ameco Research A significant portion of the population over the age of 60, who often have reduced immunity levels and are more susceptible to neurological disorders, cardiac issues, tumors, and spinal cord compression, is anticipated to have a substantial
Pediatric Radiology Market Size will Grow at CAGR 7.7% CAGR during 2017-2026
Pediatric Radiology Market:Overview The pediatric radiology market is likely to register robust growth in the near future. Chronic illnesses among children including neurological disorders such as ADHD are on the rise. According to the US labor bureau, the demand for pediatrician is expected to grow by 24% on average by 2020. This is the highest average growth among all professionals in the United States. Despite challenges such as training for new